Ying Cheng

2.7k total citations
62 papers, 702 citations indexed

About

Ying Cheng is a scholar working on Oncology, Epidemiology and Molecular Biology. According to data from OpenAlex, Ying Cheng has authored 62 papers receiving a total of 702 indexed citations (citations by other indexed papers that have themselves been cited), including 41 papers in Oncology, 18 papers in Epidemiology and 16 papers in Molecular Biology. Recurrent topics in Ying Cheng's work include Lung Cancer Research Studies (28 papers), Neuroendocrine Tumor Research Advances (14 papers) and Peptidase Inhibition and Analysis (9 papers). Ying Cheng is often cited by papers focused on Lung Cancer Research Studies (28 papers), Neuroendocrine Tumor Research Advances (14 papers) and Peptidase Inhibition and Analysis (9 papers). Ying Cheng collaborates with scholars based in China, United States and France. Ying Cheng's co-authors include Shuang Zhang, Changliang Yang, Jingjing Liu, Lixia Ma, Ying Wang, Ying Xin, Shuang Li, Jing Zhu, Ying Liu and Zhigang Tian and has published in prestigious journals such as Proceedings of the National Academy of Sciences, Journal of Clinical Oncology and SHILAP Revista de lepidopterología.

In The Last Decade

Ying Cheng

53 papers receiving 693 citations

Peers

Ying Cheng
Man Jiang China
Julie Collins United States
M Kowalska Poland
Weijie Cao China
Yasuto Yoneshima Japan
Kaushal Parikh United States
Afshin Moradi Iran
Eric S. Christenson United States
Nobuhiro Ikuno Japan
Man Jiang China
Ying Cheng
Citations per year, relative to Ying Cheng Ying Cheng (= 1×) peers Man Jiang

Countries citing papers authored by Ying Cheng

Since Specialization
Citations

This map shows the geographic impact of Ying Cheng's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Ying Cheng with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Ying Cheng more than expected).

Fields of papers citing papers by Ying Cheng

Since Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Ying Cheng. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Ying Cheng. The network helps show where Ying Cheng may publish in the future.

Co-authorship network of co-authors of Ying Cheng

This figure shows the co-authorship network connecting the top 25 collaborators of Ying Cheng. A scholar is included among the top collaborators of Ying Cheng based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Ying Cheng. Ying Cheng is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

20 of 20 papers shown
1.
2.
Cao, Kai, Guocan Wang, T. Mark Harrison, et al.. (2025). Late Cenozoic river reorganization related to tectonic extrusion formed the modern drainage system in southeastern Tibet. Proceedings of the National Academy of Sciences. 122(40). e2424554122–e2424554122. 1 indexed citations
3.
Lu, Yuanhua, Hui Li, Lin Tian, et al.. (2024). Dynamic phenotypic reprogramming and chemoresistance induced by lung fibroblasts in small cell lung cancer. Scientific Reports. 14(1). 2884–2884. 9 indexed citations
4.
Lu, Yuanhua, Hui Li, Xinyue Wang, et al.. (2024). Crosstalk between cancer-associated fibroblasts and non-neuroendocrine tumor cells in small cell lung cancer involves in glycolysis and antigen-presenting features. Molecular Medicine. 30(1). 274–274. 3 indexed citations
5.
Song, Zheng, Ying Cheng, Haiyan Yang, et al.. (2024). Final Analysis of a Phase 1 Study of Zanubrutinib Plus Lenalidomide in Patients With Relapsed/Refractory Diffuse Large B-cell Lymphoma. Blood. 144(Supplement 1). 986–986. 1 indexed citations
6.
Owonikoko, Taofeek K., Lauren A. Byers, Ying Cheng, et al.. (2024). IDeate-Lung02: A phase 3, randomized, open-label study of ifinatamab deruxtecan (I-DXd) vs treatment of physician’s choice (TPC) in relapsed small cell lung cancer (SCLC).. Journal of Clinical Oncology. 42(16_suppl). TPS8126–TPS8126. 8 indexed citations
7.
Cheng, Ying, Yu-Jung Kim, Alejandro Navarro, et al.. (2024). OA04.03 Ifinatamab Deruxtecan (I-DXd) in Extensive-Stage Small Cell Lung Cancer (ES-SCLC): Interim Analysis of Ideate-lung01. Journal of Thoracic Oncology. 19(10). S15–S16. 14 indexed citations
8.
Li, Hui, Linwei Tian, Yuanhua Lu, et al.. (2024). Advances in biomarkers for immunotherapy in small-cell lung cancer. Frontiers in Immunology. 15. 1490590–1490590. 3 indexed citations
9.
Zhou, Caicun, Yi Hu, Kejing Ying, et al.. (2023). 540P Phase III study of serplulimab plus chemotherapy as first-line therapy for advanced squamous non-small cell lung cancer: ASTRUM-004 Asian subgroup. Annals of Oncology. 34. S1680–S1680. 1 indexed citations
10.
Cui, Yanan, et al.. (2023). Potential value of efficacy prediction and treatment of natural killer cells in extensive stage small cell lung cancer. Thoracic Cancer. 14(10). 864–872. 1 indexed citations
11.
12.
Cheng, Ying, et al.. (2023). Bispecific NK-cell engager targeting BCMA elicits stronger antitumor effects and produces less proinflammatory cytokines than T-cell engager. Frontiers in Immunology. 14. 1113303–1113303. 13 indexed citations
13.
Zhang, Shuang & Ying Cheng. (2023). Immunotherapy for extensive-stage small-cell lung cancer: current landscape and future perspectives. Frontiers in Oncology. 13. 1142081–1142081. 18 indexed citations
14.
Cao, Guoshuai, Ying Cheng, Xiaodong Zheng, et al.. (2021). All‐trans retinoic acid induces leukemia resistance to NK cell cytotoxicity by down‐regulating B7‐H6 expression via c‐Myc signaling. Cancer Communications. 41(1). 51–61. 6 indexed citations
15.
Qu, Yue, et al.. (2020). WDR5 Promotes Proliferation and Correlates with Poor Prognosis in Oesophageal Squamous Cell Carcinoma. SHILAP Revista de lepidopterología. 1 indexed citations
16.
Wu, Xiaohua, Jianqing Zhu, Jun Wang, et al.. (2020). 820P Phase II study of pamiparib in Chinese patients (pts) with advanced ovarian cancer (aOC). Annals of Oncology. 31. S619–S620. 2 indexed citations
17.
Chen, Gang, Yang Wang, Li Zhang, et al.. (2019). Identification of candidate biomarkers correlated with the diagnosis and prognosis of cervical cancer via integrated bioinformatics analysis. SHILAP Revista de lepidopterología. 3 indexed citations
18.
19.
Cheng, Ying, Hui Li, Shuang Zhang, et al.. (2013). Detection of c‐kit mutational status in small‐cell lung cancer in a Chinese cohort. Thoracic Cancer. 5(3). 225–231. 1 indexed citations
20.
Cheng, Ying. (2002). The Magnificent Sun VS.the Graceful Moon——a proposed analysis of the differences between Romeo and Juliet and The Story of the Butterflies and the cultural contributing factors of these differences.

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact

Breakdown of academic impact, for papers by Man Jiang Breakdown of academic impact, for papers by Julie Collins Breakdown of academic impact, for papers by M Kowalska Breakdown of academic impact, for papers by Weijie Cao Breakdown of academic impact, for papers by Yasuto Yoneshima Breakdown of academic impact, for papers by Kaushal Parikh Breakdown of academic impact, for papers by Afshin Moradi Breakdown of academic impact, for papers by Eric S. Christenson Breakdown of academic impact, for papers by Nobuhiro Ikuno
Rankless by CCL
2026